Bird & Bird contributes to LexisNexis Market Standards Trend Report: Trends in UK Public M&A deals in 2023

Written By

simonp allport module
Simon Allport

Partner
UK

Based in London, I am a partner in Bird & Bird's International Corporate Group.

nick odonnell Module
Nick O'Donnell

Partner
UK

A seasoned partner in the London Corporate team, I have over 20 years' experience covering cross-border M&A (public and private), equity capital markets and public company governance including ESG.

Discover the latest insights from report and the outlook for 2024.

 

Topics covered include:

  • Outlook for 2024
  • Deal value and deal volume
  • Deal structure
  • Unrecommended, competing and mandatory offers
  • Public to private (P2P) transactions
  • Bidder jurisdiction
  • Industry
  • Offer timetables
  • Bid financing
  • Shareholder engagement
  • Legal and regulatory developments

Simon Allport and Nick O’Donnell, partners at Bird & Bird contributed insights on the report’s findings. Simon commented, “That the volume of deals in 2023 remained relatively static year on year is reflective of a market that is neither particularly buoyant, nor significantly depressed. There are still deals to be done, but there continues to be a level of caution, given the geo-political and economic climate. We expect this to continue into 2024.” Nick O’Donnell also commented, “In our view, the large proportion of US and other overseas bidders has contributed to schemes, as the nearest equivalent to a Delaware merger, continuing to cement their position as the default deal structure. This resulted, anecdotally, in 2023 being a year when court availability has become a preoccupation for many a deal team.”

You can register to download a copy of the report here

Latest insights

More Insights
Competition and EU

Competitive Edge: Competition & EU Law - FDI special edition - October 2024

Oct 30 2024

Read More
Mouse and keyboard

Women in Tech: At the forefront of innovation - Key takeaways from Dr. Sabine Wiesmüller, Start2Group

Oct 28 2024

Read More
Pills lined up on blue background

Licensing and Collaborations in Life Sciences

Oct 28 2024

Read More